Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 68Neoplasms 25Breast Neoplasms 15Squamous Cell Carcinoma of Head and Neck 13Lung Neoplasms 12Head and Neck Neoplasms 11Neoplasm Metastasis 8Carcinoma, Squamous Cell 7Pancreatic Neoplasms 6Colorectal Neoplasms 6Stomach Neoplasms 5Esophageal Squamous Cell Carcinoma 5Prostatic Neoplasms 4Multiple Myeloma 4Esophageal Neoplasms 4Lymphoma 3Hematologic Neoplasms 3Glioblastoma 3Brain Neoplasms 3Adenocarcinoma 3Urinary Bladder Neoplasms 2Solid Tumors 2Non-small-cell Lung Cancer With Somatic EGFR Mutations 2NSCLC 2Melanoma 2Glioma 2Colonic Neoplasms 2Adenocarcinoma of Lung 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1

Interventions

zenocutuzumab 1enzalutamide 1Afatinib 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NSCLC Harboring NRG1 Fusion × Afatinib × Clear all
NCT05588609 2026-04-27

Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

Partner Therapeutics, Inc.

Phase 2 Terminated
13 enrolled
GenitourinaryThoracic

NSCLC Harboring NRG1 Fusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡